Leukine (sargramostim) / Partner Therap 
Welcome,         Profile    Billing    Logout  
 449 Diseases   58 Trials   58 Trials   3605 News 


«12...678910111213141516...2425»
  • ||||||||||  Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
    Trial primary completion date:  NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) -  Jul 30, 2019   
    P2,  N=64, Active, not recruiting, 
    This ongoing phase II study may define a broader role for naxitamab which was recently granted breakthrough designation by the Federal Drug Administration of the US. Trial primary completion date: Jun 2019 --> Nov 2019
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Biomarker, Enrollment closed, Trial completion date, Trial primary completion date:  Biomarker Assessments of Leukine During Treatment of Parkinson's Disease (clinicaltrials.gov) -  Jul 25, 2019   
    P1,  N=5, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Jul 2019 Recruiting --> Active, not recruiting | Trial completion date: Apr 2020 --> Dec 2020 | Trial primary completion date: Jan 2020 --> Sep 2020
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Enrollment closed, Trial primary completion date, Immunomodulating:  GM-CSF for Immunomodulation Following Trauma (GIFT) Study (clinicaltrials.gov) -  Jul 22, 2019   
    P4,  N=200, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Apr 2020 --> Dec 2020 | Trial primary completion date: Jan 2020 --> Sep 2020 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2019 --> Dec 2019
  • ||||||||||  Recentin (cediranib) / AstraZeneca
    Trial completion date, Trial primary completion date, Monotherapy, Metastases:  Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) -  Jul 18, 2019   
    P2,  N=70, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2019 --> Dec 2019 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's
    Enrollment change:  VADIS: Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer (clinicaltrials.gov) -  Jul 18, 2019   
    P2,  N=13, Active, not recruiting, 
    Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020 N=108 --> 13
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
    Trial primary completion date, Combination therapy:  Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma (clinicaltrials.gov) -  Jun 7, 2019   
    P2,  N=44, Active, not recruiting, 
    Trial completion date: Apr 2021 --> Jul 2021 Trial primary completion date: Jun 2019 --> Dec 2019
  • ||||||||||  Enrollment closed, Trial primary completion date:  SPRING: High-Risk Neuroblastoma Chemotherapy Without G-CSF (clinicaltrials.gov) -  May 31, 2019   
    P=N/A,  N=13, Active, not recruiting, 
    We will also examine future studies and challenges facing the translation of this therapeutic approach. Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> Mar 2019
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
    Trial completion date, Trial primary completion date:  Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) -  May 14, 2019   
    P2,  N=52, Active, not recruiting, 
    Trial completion date: Sep 2019 --> Sep 2020 Trial completion date: Jan 2020 --> Jan 2021 | Trial primary completion date: Jan 2019 --> Jan 2020
  • ||||||||||  UV1 / Ultimovacs
    Trial completion date, Trial primary completion date:  A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer. (clinicaltrials.gov) -  May 7, 2019   
    P1/2,  N=18, Active, not recruiting, 
    Trial completion date: Jan 2020 --> Jan 2021 | Trial primary completion date: Jan 2019 --> Jan 2020 Trial completion date: Feb 2020 --> Apr 2023 | Trial primary completion date: Feb 2020 --> Apr 2023
  • ||||||||||  UV1 / Ultimovacs
    Trial completion date, Trial primary completion date, Metastases:  A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer (clinicaltrials.gov) -  May 7, 2019   
    P1/2,  N=21, Active, not recruiting, 
    Trial completion date: Feb 2020 --> Apr 2023 | Trial primary completion date: Feb 2020 --> Apr 2023 Trial completion date: Jul 2020 --> Apr 2023 | Trial primary completion date: Jul 2020 --> Apr 2023
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Trial completion, Enrollment change, Post-transplantation:  Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation (clinicaltrials.gov) -  May 6, 2019   
    P1,  N=22, Completed, 
    Trial completion date: Nov 2019 --> Feb 2025 | Trial primary completion date: Nov 2019 --> Feb 2020 Active, not recruiting --> Completed | N=40 --> 22
  • ||||||||||  Neupogen (filgrastim) / Kyowa Hakko Kirin, Roche, Amgen
    Journal:  Monocytopenia in clozapine-induced agranulocytosis: insights into pathophysiology and treatment. (Pubmed Central) -  May 5, 2019   
    ...Clozapine was held and the patient was started on granulocyte colony-stimulating factor (G-CSF) filgrastim and received two doses without any signs of ANC recovery...Therefore, sargramostim GM-CSF was started...Thus, we demonstrate a case of monocytopenia accompanying clozapine-induced agranulocytosis with successful use of GM-CSF. At least in this case, the target of the clozapine injury appears to be the CFU-GM, explaining the rapid and full response to GM-CSF after lack of response to G-CSF.
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
    Phase classification, Combination therapy, Metastases:  PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) -  Apr 20, 2019   
    P1/2,  N=51, Completed, 
    At least in this case, the target of the clozapine injury appears to be the CFU-GM, explaining the rapid and full response to GM-CSF after lack of response to G-CSF. Phase classification: P2 --> P1/2
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Trial completion date, Trial primary completion date:  Study of the Safety & Efficacy of Leukine (clinicaltrials.gov) -  Apr 20, 2019   
    P2,  N=40, Active, not recruiting, 
    Phase classification: P2 --> P1/2 Trial completion date: Nov 2019 --> May 2020 | Trial primary completion date: Feb 2019 --> May 2020
  • ||||||||||  Leukine (sargramostim) / Partner Therap, NN1213 / Novo Nordisk
    Trial completion date:  The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer (clinicaltrials.gov) -  Apr 19, 2019   
    P1,  N=19, Active, not recruiting, 
    Trial completion date: Mar 2019 --> Jun 2019 Trial completion date: Dec 2018 --> Dec 2019
  • ||||||||||  Zeltherva (galinpepimut-S) / SELLAS Life Sciences
    Trial initiation date, BRCA Biomarker, PD(L)-1 Biomarker, Metastases:  Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers (clinicaltrials.gov) -  Apr 4, 2019   
    P1/2,  N=90, Recruiting, 
    Trial completion date: Dec 2020 --> Mar 2021 | Trial primary completion date: Dec 2019 --> Mar 2021 Initiation date: Dec 2018 --> Apr 2019
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  iGRASP: Inhaled GM-CSF for Respiratory Virus-Associated Severe Pneumonia (clinicaltrials.gov) -  Mar 26, 2019   
    P1,  N=0, Withdrawn, 
    The addition of ERC1671/GM-CSF/cyclophosphamide to bevacizumab resulted in a clinically meaningful survival benefit with minimal additional toxicity. N=12 --> 0 | Trial completion date: Dec 2017 --> May 2019 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> May 2019
  • ||||||||||  Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
    Trial completion date, Trial primary completion date:  NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) -  Mar 15, 2019   
    P2,  N=64, Active, not recruiting, 
    N=12 --> 0 | Trial completion date: Dec 2017 --> May 2019 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> May 2019 Trial completion date: May 2019 --> May 2020 | Trial primary completion date: Feb 2019 --> Jun 2019
  • ||||||||||  Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche
    Trial completion:  Neoadjuvant Treatment of Breast Cancer (clinicaltrials.gov) -  Feb 28, 2019   
    P2,  N=43, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed
  • ||||||||||  Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's
    Enrollment closed, Trial primary completion date:  VADIS: Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer (clinicaltrials.gov) -  Feb 22, 2019   
    P2,  N=108, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2019 --> Mar 2019
  • ||||||||||  EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
    Trial completion date, Trial primary completion date, Combination therapy, IO biomarker, Metastases:  NCI-2015-01942: BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer (clinicaltrials.gov) -  Feb 12, 2019   
    P1/2,  N=2, Active, not recruiting, 
    Active, not recruiting --> Suspended Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
    Enrollment closed, Combination therapy, Metastases:  Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) -  Feb 7, 2019   
    P1,  N=42, Active, not recruiting, 
    Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020 Completed --> Active, not recruiting
  • ||||||||||  Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap, NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma (clinicaltrials.gov) -  Jan 29, 2019   
    P1/2,  N=40, Recruiting, 
    Trial completion date: Mar 2018 --> Dec 2020 | Trial primary completion date: Mar 2018 --> Dec 2019 Trial completion date: May 2018 --> Dec 2019 | Trial primary completion date: May 2018 --> Dec 2019